대한의생명과학회지 (Biomedical Science Letters)

  • 제29권4호
  • /
  • Pages.382-385
  • /
  • 2023
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Niclosamide Enhances NK cell Proliferation and Anti-Tumor Activity for Cancer Immunotherapy

  • Min Hwa Shin (Immune Research Institute, Seegene Medical Foundation)
  • 투고 : 2023.11.26
  • 심사 : 2023.12.13
  • 발행 : 2023.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

NK (Natural killer) cells are innate immune cells and play important roles as the first immune cells to act when cancer occurs. In many cancer patients, NK cells can be seen to be inactivated, suggesting that NK cells are important in cancer treatment. In order to overcome the disadvantages of NK cells in cancer treatment, it is critical to develop strategies that enhance the proliferation and cytolytic function of NK cells. We applied niclosamide to measure the degree of NK cell activation, and obtained unexpected results of increased NK cell numbers and anti-tumor activity. Although further investigation is required to uncover the detailed mechanisms, our results suggest that Niclosamide is a promising candidate to increase the efficacy of cancer immunotherapy using NK cells.

키워드

참고문헌

  1. Al-Kuraishy HM, Al-Gareeb AI, Alzahrani KJ, Alexiou A, Batiha GE. Niclosamide for covid-19: Bridging the gap. Mol Biol Rep. 2021. 48: 8195-8202. https://doi.org/10.1007/s11033-021-06770-7
  2. Chen W, Mook RA, Jr., Premont RT, Wang J. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018. 41: 89-96. https://doi.org/10.1016/j.cellsig.2017.04.001
  3. Jiang H, Li AM, Ye J. The magic bullet: Niclosamide. Front Oncol. 2022. 12: 1004978.
  4. Laskowski TJ, Biederstadt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nature Reviews Cancer. 2022. 22: 557-575. https://doi.org/10.1038/s41568-022-00491-0
  5. Li Y, Li PK, Roberts MJ, Arend RC, Samant RS, Buchsbaum DJ. Multi-targeted therapy of cancer by niclosamide: A new application for an old drug. Cancer Lett. 2014. 349: 8-14. https://doi.org/10.1016/j.canlet.2014.04.003
  6. Lim SA, Moon Y, Shin MH, Kim TJ, Chae S, Yee C, Hwang D, Park H, Lee KM. Hypoxia-driven hif-1α activation reprograms pre-activated nk cells towards highly potent effector phenotypes via erk/stat3 pathways. Cancers (Basel). 2021. 13.
  7. Luo F, Luo M, Rong QX, Zhang H, Chen Z, Wang F, Zhao HY, Fu LW. Niclosamide, an antihelmintic drug, enhances efficacy of pd-1/pd-l1 immune checkpoint blockade in non-small cell lung cancer. J Immunother Cancer. 2019. 7: 245.
  8. Pearson RD, Hewlett EL. Niclosamide therapy for tapeworm infections. Ann Intern Med. 1985. 102: 550-551. https://doi.org/10.7326/0003-4819-102-4-550
  9. Ren J, Wang B, Wu Q, Wang G. Combination of niclosamide and current therapies to overcome resistance for cancer: New frontiers for an old drug. Biomedicine & Pharmacotherapy. 2022. 155: 113789.
  10. Shin MH, Kim J, Lim SA, Kim J, Kim SJ, Lee KM. Nk cell-based immunotherapies in cancer. Immune Netw. 2020. 20: e14.
  11. Shin MH, Oh E, Kim Y, Nam DH, Jeon SY, Yu JH, Minn D. Recent advances in car-based solid tumor immunotherapy. Cells. 2023. 12.
  12. Sordo-Bahamonde C, Lorenzo-Herrero S, Payer AR, Gonzalez S, Lopez-Soto A. Mechanisms of apoptosis resistance to nk cell-mediated cytotoxicity in cancer. Int J Mol Sci. 2020. 21.
  13. Wang Z, Ren J, Du J, Wang H, Liu J, Wang G. Niclosamide as a promising therapeutic player in human cancer and other diseases. Int J Mol Sci. 2022. 23.